1-Piperidinebutanesulfonic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Piperidinebutanesulfonic acid
• 英文别名: 4-piperidin-1-ylbutane-1-sulfonic acid
• 化学式: C₉H₁₉NO₃S
• 分子量: 221.32
• InChiKey: RQXWBNSARKOVJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Methods and compositions for treating amyloid-related diseases
  申请人：Kong Xianqi

  公开号：US20070010573A1

  公开（公告）日：2007-01-11

  Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

  描述了用于治疗或预防与淀粉样蛋白相关的疾病的方法、化合物、制药组合物和试剂盒。
• Compositions and methods for treating amyloidosis
  申请人：Szarek Walter

  公开号：US20090099100A1

  公开（公告）日：2009-04-16

  Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amount of a therapeutic compound of the formula or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. R 1 and R 2 are each independently a hydrogen atom or a substituted or unsubstituted aliphatic or aryl group. Z and Q are each independently a carbonyl (C═O), thiocarbonyl (C═S), sulfonyl (SO 2 ), or sulfoxide (S═O) group. “k” and “m” are 0 or 1, provided when k is 1, R 1 is not a hydrogen atom, and when m is 1, R 2 is not a hydrogen atom. In an embodiment, at least one of k or m must equal 1. “p” and “s” are each independently positive integers selected such that the biodistribution of the therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound. T is a linking group and Y is a group of the formula -A X wherein A is an anionic group at physiological pH, and X is a cationic group.

  本文描述了用于调节主体中淀粉样聚集物的治疗化合物和方法，无论其临床设置如何。通过向主体投予公式中的治疗化合物或其药学上可接受的盐或酯的有效量，从而调节淀粉样聚集物的聚集。其中，R1和R2分别独立地是氢原子或取代或未取代的脂肪族或芳香族基团。Z和Q分别独立地是羰基（C═O），硫代羰基（C═S），磺酰基（SO2）或亚砜基（S═O）基团。“k”和“m”均为0或1，当k为1时，R1不是氢原子，当m为1时，R2不是氢原子。在一种实施例中，k或m中至少有一个必须等于1。“p”和“s”分别独立地是正整数，选取这些正整数以便在维持治疗化合物的活性的同时，不会阻止治疗化合物对预期靶位点的生物分布。T是一个连接基团，而Y是一个公式为-A X的基团，其中A是生理pH下的阴离子基团，而X是一个阳离子基团。
• Methods and Compositions for Treating Amyloid-Related Diseases
  申请人：KONG Xianqi

  公开号：US20100190753A1

  公开（公告）日：2010-07-29

  Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.

  本文描述了用于治疗或预防淀粉样蛋白相关疾病的方法、化合物、药物组合物和试剂盒。
• METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES
  申请人：Kong Xianqi

  公开号：US20100113591A1

  公开（公告）日：2010-05-06

  Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

  本发明涉及用于治疗或预防淀粉样蛋白相关疾病的方法、化合物、制药组合物和试剂盒。
• Amyloid targeting imaging agents and uses thereof
  申请人：——

  公开号：US20020115717A1

  公开（公告）日：2002-08-22

  Amyloid-targeting imaging agents such as radiolabeled amyloid targeting molecules and amyloid targeting molecule-chelator conjugates for imaging, e.g., amyloid plaques in vivo, and/or for the treatment of amyloidosis disorders. The invention provides amyloid-targeting imaging agents that are useful for imaging sites of amyloid disease. Imaging agents of the invention are capable of binding specifically to amyloid plaques, as an aid in diagnosis and/or early treatment of amyloidosis disorders.

  淀粉样蛋白靶向成像剂，如放射性标记的淀粉样蛋白靶向分子和淀粉样蛋白靶向分子-螯合剂共轭物，用于例如体内淀粉样蛋白斑块的成像，和/或用于淀粉样变性疾病的治疗。本发明提供的淀粉样蛋白靶向成像剂可用于淀粉样蛋白疾病部位的成像。本发明的成像剂能够与淀粉样蛋白斑块特异性结合，有助于淀粉样变性疾病的诊断和/或早期治疗。